Literature DB >> 22089392

High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome.

Tomoki Origuchi1, Kazuhiko Arima, Shin-Ya Kawashiri, Mami Tamai, Satoshi Yamasaki, Hideki Nakamura, Toshiaki Tsukada, Toshiyuki Aramaki, Masako Furuyama, Taiichiro Miyashita, Yojiro Kawabe, Nozomi Iwanaga, Kaoru Terada, Yukitaka Ueki, Takaaki Fukuda, Katsumi Eguchi, Atsushi Kawakami.   

Abstract

Recently, it was reported that remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome could be complicated with solid tumors. In a retrospective, multicenter study between October, 2003 and September, 2010, we investigated the characteristics of patients with paraneoplastic RS3PE syndrome who fulfilled following criteria: (1) bilateral pitting edema of hands or feet or both, (2) sudden onset of polyarthritis, and (3) age >50 years, (4) seronegativity for rheumatoid factor (RF). A total of 33 cases fulfilled the above criteria. Eight patients (seven men and one woman) developed cancer within 2 years of RS3PE syndrome onset. There was no significant difference between the neoplastic and nonneoplastic groups in the proportions of patients with fever, symmetrical polyarthritis, pitting edema, and good response to corticosteroids. Serum matrix metalloproteinase 3 (MMP-3) level (median 437.3 ng/ml) in the paraneoplastic RS3PE patients was significantly higher than that in patients without neoplasia (median 114.7 ng/ml) (p < 0.05). We found that high serum MMP-3 is characteristic of patients with paraneoplastic RS3PE syndrome.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22089392     DOI: 10.1007/s10165-011-0556-y

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  13 in total

1.  Lucky to meet RS3PE.

Authors:  Cláudia Ferrao; Raquel M Faria; Pedro Farrajota; Carlos Vasconcelos
Journal:  BMJ Case Rep       Date:  2013-10-07

Review 2.  Lung cancer mimicking systemic lupus erythematosus: case-based review.

Authors:  Jia Liu; Song Hu; Min Niu; Hua Wang; Yan Wang; Ning Tang; Bin Liu
Journal:  Rheumatol Int       Date:  2019-10-14       Impact factor: 2.631

Review 3.  Paraneoplastic syndromes in rheumatology.

Authors:  Bernhard Manger; Georg Schett
Journal:  Nat Rev Rheumatol       Date:  2014-08-19       Impact factor: 20.543

Review 4.  RS3PE: Clinical and Research Development.

Authors:  Hongbin Li; Roy D Altman; Qingping Yao
Journal:  Curr Rheumatol Rep       Date:  2015-08       Impact factor: 4.592

Review 5.  Paraneoplastic musculoskeletal disorders: review and update for radiologists.

Authors:  Kimia Khalatbari Kani; Jack A Porrino; Michael E Mulligan; Felix S Chew
Journal:  Skeletal Radiol       Date:  2022-05-23       Impact factor: 2.199

6.  RS3PE Following Treatment With Combination of Hormonal Therapies Plus Ipilimumab in a Patient With Metastatic Prostate Cancer.

Authors:  Sang T Kim; William A Murphy; Ana Aparicio; Sumit K Subudhi
Journal:  J Immunother Precis Oncol       Date:  2020-05-14

7.  A Case of Paraneoplastic Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome Improved by Chemotherapy.

Authors:  Takahiko Sakamoto; Shuji Ota; Terunobu Haruyama; Masashi Ishihara; Maika Natsume; Yoko Fukasawa; Shigeru Tanzawa; Ryo Usui; Takeshi Honda; Yasuko Ichikawa; Kiyotaka Watanabe; Nobuhiko Seki
Journal:  Case Rep Oncol       Date:  2017-12-20

8.  RS3PE syndrome developing during the course of probable toxic shock syndrome: a case report.

Authors:  Moe Kyotani; Tsuneaki Kenzaka; Ryo Nishio; Hozuka Akita
Journal:  BMC Infect Dis       Date:  2018-04-13       Impact factor: 3.090

9.  Serum matrix metalloproteinase 3 in detecting remitting seronegative symmetrical synovitis with pitting edema syndrome: A case report.

Authors:  Tsuneaki Kenzaka; Ken Goda
Journal:  World J Clin Cases       Date:  2018-05-16       Impact factor: 1.337

10.  The Relationship between Remitting Seronegative Symmetrical Synovitis with Pitting Edema and Vascular Endothelial Growth Factor and Matrix Metalloproteinase 3.

Authors:  Tsuneaki Kenzaka
Journal:  Intern Med       Date:  2020-01-17       Impact factor: 1.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.